Some app makers worry that a slight change to the iPhone's contact-sharing permissions could make it difficult for them to achieve the rapid growth they need to compete.
The SEC complained about deficiencies in the research supporting the drug, and its developer agreed to a $40 million settlement. Some experts question why the clinical trials were not stopped.